Wegovy (semaglutide) targets GLP-1 receptors, while Zepbound (tirzepatide) targets both GLP-1 and GIP receptors
So just a little summary of the agenda today
The cardiovascular risk-reduction indication for adults with established CVD who are overweight or obese is coverable under Cigna Medicare Advantage with prior authorization
Pernicious Anemia, National Heart, Lung, and Blood Institute
A Personalized Approach to Semaglutide Therapy at PlexusDx Rather than defaulting to drug combinations lacking robust evidence, PlexusDx offers a precision-focused path: compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan, combined with optional genetic testing through the Precision Peptide Genetic Test ($99 add-on after the first month)
This treatment is designed to support energy levels, mental clarity, and metabolic health through a clinically guided approach